Macquarie and HSBC remained positive on Sun Pharma after June-quarter EBITDA and margins beat estimates, while BofA flagged slowing US and specialty sales and limited near-term catalysts.
Indian News
Sun Pharma Q1 Review: Brokerages Back India Growth, Flag Specialty Slowdown
Macquarie and HSBC remained positive on Sun Pharma after June-quarter EBITDA and margins beat estimates, while BofA flagged slowing US and specialty sales and limited near-term catalysts. Source: Read the original article on www.ndtvprofit.com